SCHEMBL30689097

SCHEMBL30689097

O=C(NCCCC[C@H](NCl)C(=O)OCc1ccccc1)OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 3/20 0.64
HTT P42858 1/20 0.60
MMP2 P08253 3/20 0.60
MMP9 P14780 3/20 0.60
TGM2 P21980 1/20 0.57
LMNA P02545 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
DPP8 Q6V1X1 1/20 0.56
DPP7 Q9UHL4 1/20 0.56
MMP1 P03956 1/20 0.55
MMP3 P08254 1/20 0.55
MMP7 P09237 1/20 0.55
MMP13 P45452 1/20 0.55
KEAP1 Q14145 1/20 0.55
NFE2L2 Q16236 1/20 0.55
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
ANPEP P15144 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25932584 0.92 CA1 (0.63) FOLH1HTTMMP2MMP9TGM2
SCHEMBL29549390 0.92 CA1 (0.63) FOLH1HTTMMP2MMP9TGM2
SCHEMBL25406900 0.92 FOLH1 (0.71) FOLH1HTTMMP2MMP9TGM2
SCHEMBL28854990 0.89 FOLH1 (0.55) FOLH1HTTMMP2MMP9TGM2
SCHEMBL26290387 0.89 FOLH1 (0.55) FOLH1HTTMMP2MMP9TGM2
SCHEMBL30689133 0.88 MAPT (0.58) FOLH1
SCHEMBL12508122 0.88 MAPT (0.61) FOLH1HTTMMP2MMP9
SCHEMBL26290597 0.88 FOLH1 (0.54) FOLH1HTTMMP2MMP9TGM2
SCHEMBL17244715 0.85 SIRT5 (0.62) FOLH1HTT
SCHEMBL18789039 0.85 FOLH1 (0.62) FOLH1HTTMMP2MMP9TGM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312644-A1 COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING SHANGHAI LUMOSA THERAPEUTICS CO LTD (CN) 2023-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312644-A1 COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING SERPINC1, PLAT, F2 FOLH1 2091/4885HTT 165/4885MMP2 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.